Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
6,775 total articles
Interparfums, Inc. delivered record net sales of $345 million and diluted EPS of $1.35 for the first quarter of 2026, reflecting organic growth driven by key brands such as Coach, Montblanc, and Roberto Cavalli. The Company maintained a strong financial position, improved gross margin, and reaffirmed its 2026 full year sales and EPS guidance while …
Freshworks Inc. reported solid financial results for Q1 2026, with total revenue of $228.6 million representing 16% year-over-year growth and a non-GAAP operating income of $41.0 million. The company secured its two largest deals ever, including the first $1 million-plus ARR contract. Despite a slight GAAP operating loss, strong cash flow and growi…
Enact Holdings, Inc. declared a 14% increase in its quarterly dividend to $0.24 per common share, payable June 18, 2026. This move reflects the company's strong financial position and confidence in its long-term outlook, balancing shareholder returns with business investment and customer support. Enact is a leading U.S. private mortgage insurance p…
Angi Inc. has published its first-quarter 2026 financial results along with a letter to shareholders from CEO Jeffrey Kip on its investor relations website. The company announced a conference call on May 6, 2026, to discuss earnings and answer investor questions, featuring both the CEO and CFO. Angi, a NASDAQ-listed company, connects homeowners wit…
Navitas Semiconductor reported an 18% sequential revenue increase in Q1 2026, fueled by growth in high-power markets such as AI data centers, grid and energy infrastructure, performance computing, and industrial electrification. The company is transitioning focus away from mobile and consumer segments towards high-power semiconductor solutions usin…
Nasdaq announced the release of its monthly trading volume statistics for April 2026, available on its Investor Relations website. The update provides transparency on trading activity across Nasdaq's markets and supports the ongoing monitoring of market liquidity and performance.
Cytokinetics reported strong initial sales of MYQORZO following its U.S. launch in late January 2026 with over 275 healthcare providers prescribing to approximately 680 patients, generating $4.8 million net revenue in Q1. The company announced positive top-line results from the ACACIA-HCM Phase 3 trial, showing efficacy in non-obstructive hypertrop…
Astera Labs announced strong first quarter fiscal 2026 financial results with record revenue of $308.4 million, reflecting 14% sequential growth and 93% year-over-year increase. The company highlighted robust demand for its PCIe 6 portfolio and newly launched Scorpio X-Series 320-lane AI fabric switch, aimed at frontier AI workloads. Astera Labs al…
Myriad Genetics announced Q1 2026 financial results showing a 2% revenue growth to $200.4 million driven by strong volumes in Cancer Care Continuum and Mental Health testing, offsetting declines in Prenatal Health. The company launched the Precise MRD assay and received FDA approval for MyChoice CDx test as a companion diagnostic for Zejula® in ova…
BlackLine, Inc. announced solid financial results for the first quarter of 2026, with 9.7% revenue growth year over year to $183.2 million, improved GAAP and non-GAAP operating margins, and increased net income. The company highlighted the commercial adoption of its AI-driven platform capabilities and raised its full-year financial guidance, expect…
Adaptive Biotechnologies reported a 35% year-over-year revenue increase to $70.9 million in Q1 2026, driven primarily by a 53% growth in its Minimal Residual Disease (MRD) business. The company enhanced its full-year MRD revenue guidance to $260-270 million. Despite a net loss of $20 million, this was an improvement compared to the prior year, with…
Cricut, Inc. announced its first quarter 2026 financial results with revenue of $159.5 million, down 2% year-over-year, and net income of $20.3 million, down 15% year-over-year. The company reported growth in its platform revenue by nearly 6% and an increase in paid subscribers to just under 3.08 million. International revenue rose over 16%, making…
Trevi Therapeutics announced strong first quarter 2026 financial results, highlighted by a $162 million net cash infusion from a follow-on stock offering, ensuring funding through 2030. The company is progressing on multiple clinical fronts for its investigational drug Haduvio in treating IPF-related chronic cough, non-IPF ILD-related chronic cough…
Talen Energy Corporation reported a robust first quarter 2026 with GAAP net income of $63 million, adjusted EBITDA of $473 million, and adjusted free cash flow of $350 million—substantial year-over-year improvements. The company reaffirmed its 2026 financial guidance ranges and announced a definitive agreement to acquire three power plants in India…
Korro Bio, a biopharmaceutical company specializing in RNA editing through its OPERA® platform, announced that key executives will participate in the HCW 4th Annual BioConnect Nasdaq Investor Conference and the 2026 RBC Capital Markets Global Healthcare Conference. These engagements aim to present their innovative genetic medicine programs and stra…
Caribou Biosciences announced that its CEO, Dr. Rachel Haurwitz, will participate in a fireside chat at the upcoming Bank of America Securities 2026 Health Care Conference. The company is a clinical-stage biopharmaceutical firm specializing in CRISPR genome-editing for therapies targeting hematologic malignancies with off-the-shelf CAR-T cell treat…
ServiceTitan, a software platform specializing in AI-driven solutions for trade contractors, announced it will release its fiscal first quarter 2027 financial results on June 4, 2026, followed by a conference call to discuss the results and fiscal year 2027 outlook. The company provides AI-powered workflow automation for contracting businesses acro…
Alamar Biosciences, a leader in Precision Proteomics, announced it will present at the BofA Securities 2026 Healthcare Conference, showcasing its NULISA technology and ARGO HT System aimed at early disease detection through biomarker analysis.
American Coastal Insurance Corporation reported net income of $19.3 million for Q1 2026, slightly down 9.8% year-over-year. Gross premiums written fell 24.5% to $149.4 million due to a softening commercial insurance market and pricing pressure. The company maintained solid underwriting discipline with a combined ratio of 66.0%. Book value per share…
MYR Group Inc., a leading specialty electrical contractor in the U.S. and Canada, will participate in the Baird Global Consumer, Technology & Services Conference on June 4, 2026, to meet with institutional investors and present its business operations across the electric utility infrastructure and commercial-industrial construction markets.
Spero Therapeutics, a clinical-stage biopharmaceutical company focused on rare diseases and high unmet needs, plans to release its Q1 2026 financial results and provide a business update on May 13, 2026, after market close. No conference call is scheduled.
Weyco Group, Inc. announced first quarter 2026 financial results with net sales steady at $68 million compared to Q1 2025. Operating earnings rose by 7%, and net earnings increased by 10%, driven by improved cost controls despite tariff-related cost pressures. The company is actively engaging in a tariff refund process following a Supreme Court rul…
Sana Biotechnology, a US-based biotech company specializing in engineered cell therapies, announced it will present a business overview and company updates at the BofA Securities 2026 Healthcare Conference on May 12, 2026. The presentation by CEO Steve Harr will detail Sana's strategy and vision for advancing gene and cell therapies. The webcast wi…
OnKure Therapeutics reported Q1 2026 financial results highlighting a strategic focus on next-generation PI3Kα pan-mutant selective inhibitors, OKI-355 for vascular anomalies and OKI-345 for breast cancer. The company completed an oversubscribed $150 million private placement, boosting cash reserves to $192 million, expected to fund operations into…
Verrica Pharmaceuticals announced the presentation of Phase 2 clinical data highlighting the potential abscopal effects of their novel oncolytic peptide VP-315 in treating basal cell carcinoma (BCC). The data suggest VP-315 can reduce untreated tumor lesions, indicating broader immune activation that may benefit patients with multiple BCC lesions. …
